126 related articles for article (PubMed ID: 1507198)
1. Mapping the binding site of tissue kallikrein: preparation and testing of all possible substrate analog inhibitors homologous with the sequence of kininogen between Ser386 and Gln392.
Deshpande MS; Burton J
J Med Chem; 1992 Aug; 35(17):3094-102. PubMed ID: 1507198
[TBL] [Abstract][Full Text] [Related]
2. A systematic approach for determining minimum inhibitory sequence and contribution of individual residues in binding of kininogen fragments to tissue kallikrein.
Deshpande MS; Burton J
Agents Actions Suppl; 1992; 38 ( Pt 1)():210-6. PubMed ID: 1466273
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the extent of the binding site in human tissue kallikrein by synthetic substrates with sequences of human kininogen fragments.
Del Nery E; Chagas JR; Juliano MA; Prado ES; Juliano L
Biochem J; 1995 Nov; 312 ( Pt 1)(Pt 1):233-8. PubMed ID: 7492318
[TBL] [Abstract][Full Text] [Related]
4. Effects of secondary interactions on the kinetics of peptide and peptide ester hydrolysis by tissue kallikrein and trypsin.
Fiedler F
Eur J Biochem; 1987 Mar; 163(2):303-12. PubMed ID: 3643848
[TBL] [Abstract][Full Text] [Related]
5. Design, structure-activity, and molecular modeling studies of potent renin inhibitory peptides having N-terminal Nin-For-Trp (Ftr): angiotensinogen congeners modified by P1-P1' Phe-Phe, Sta, Leu psi[CH(OH)CH2]Val or leu psi[CH2NH]Val substitutions.
Sawyer TK; Pals DT; Mao B; Staples DJ; de Vaux AE; Maggiora LL; Affholter JA; Kati W; Duchamp D; Hester JB
J Med Chem; 1988 Jan; 31(1):18-30. PubMed ID: 3275777
[TBL] [Abstract][Full Text] [Related]
6. Substrate specificity of porcine pancreatic kallikrein.
Fiedler F; Leysath G
Adv Exp Med Biol; 1979; 120A():261-71. PubMed ID: 495315
[TBL] [Abstract][Full Text] [Related]
7. Mapping the active sites of bovine thrombin, factor IXa, factor Xa, factor XIa, factor XIIa, plasma kallikrein, and trypsin with amino acid and peptide thioesters: development of new sensitive substrates.
McRae BJ; Kurachi K; Heimark RL; Fujikawa K; Davie EW; Powers JC
Biochemistry; 1981 Dec; 20(25):7196-206. PubMed ID: 6976185
[TBL] [Abstract][Full Text] [Related]
8. In vivo inhibition of tissue kallikreins by kininogen sequence analogue peptides.
Okunishi H; Spragg J; Burton J; Toda N
Adv Exp Med Biol; 1989; 247B():23-8. PubMed ID: 2481944
[TBL] [Abstract][Full Text] [Related]
9. Kininogen-derived fluorogenic substrates for investigating the vasoactive properties of rat tissue kallikreins--identification of a T-kinin-releasing rat kallikrein.
El Moujahed A; Brillard-Bourdet M; Juliano MA; Moreau T; Chagas JR; Gutman N; Prado ES; Gauthier F
Eur J Biochem; 1997 Jul; 247(2):652-8. PubMed ID: 9266709
[TBL] [Abstract][Full Text] [Related]
10. Specificity of substrate analogue inhibitors of human urinary kallikrein.
Okunishi H; Burton J; Spragg J
Hypertension; 1985; 7(3 Pt 2):I72-5. PubMed ID: 3846567
[TBL] [Abstract][Full Text] [Related]
11. Chromogenic and fluorogenic glycosylated and acetylglycosylated peptides as substrates for serine, thiol and aspartyl proteases.
Juliano MA; Filira F; Gobbo M; Rocchi R; Del Nery E; Juliano L
J Pept Res; 1999 Feb; 53(2):109-19. PubMed ID: 10195448
[TBL] [Abstract][Full Text] [Related]
12. Localization of the binding site on plasma kallikrein for high-molecular-weight kininogen to both apple 1 and apple 4 domains of the heavy chain.
Page JD; You JL; Harris RB; Colman RW
Arch Biochem Biophys; 1994 Oct; 314(1):159-64. PubMed ID: 7944388
[TBL] [Abstract][Full Text] [Related]
13. Synthesis of the segment (11-23) located in the first tandem repeat of plasma kallikrein: comparative binding studies of this and another segment (328-343) to high-molecular-mass kininogen.
Basak A; Yuan XW; Harris R; Seidah NG; Chrétien M
J Chromatogr; 1993 Jun; 615(2):251-64. PubMed ID: 8335703
[TBL] [Abstract][Full Text] [Related]
14. Comparison of human and porcine tissue kallikrein substrate specificities.
Del Nery E; Chagas JR; Juliano MA; Juliano L; Prado ES
Immunopharmacology; 1999 Dec; 45(1-3):151-7. PubMed ID: 10615005
[TBL] [Abstract][Full Text] [Related]
15. In vivo assay of specific kallikrein inhibitors.
Okunishi H; Spragg J; Burton J
Agents Actions Suppl; 1987; 22():381-90. PubMed ID: 3481213
[TBL] [Abstract][Full Text] [Related]
16. High molecular weight kininogen peptides inhibit the formation of kallikrein on endothelial cell surfaces and subsequent urokinase-dependent plasmin formation.
Lin Y; Harris RB; Yan W; McCrae KR; Zhang H; Colman RW
Blood; 1997 Jul; 90(2):690-7. PubMed ID: 9226169
[TBL] [Abstract][Full Text] [Related]
17. Comparative study of kallikrein-like serine proteinases from rat submandibular glands.
Bedi GS
Prep Biochem Biotechnol; 1996 May; 26(2):85-104. PubMed ID: 8784920
[TBL] [Abstract][Full Text] [Related]
18. The inhibition of glandular kallikrein by peptide analog antagonists of bradykinin.
Spragg J; Vavrek RJ; Stewart JM
Peptides; 1988; 9(1):203-6. PubMed ID: 3362744
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of human and rat tissue kallikreins by peptide analog antagonists of bradykinin.
Spragg J; Vavrek RJ; Stewart JM
Adv Exp Med Biol; 1989; 247B():277-81. PubMed ID: 2610073
[TBL] [Abstract][Full Text] [Related]
20. Thrombin specificity. Requirement for apolar amino acids adjacent to the thrombin cleavage site of polypeptide substrate.
Chang JY
Eur J Biochem; 1985 Sep; 151(2):217-24. PubMed ID: 2863141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
